Tuesday, August 02, 2016 11:34:25 AM
So what "Tier 3" stocks do I like as standalone entities but see as logical acquisition targets? Here are two names that should be on your shopping list.
Merrimack Pharmaceuticals (NASDAQ:MACK) - The company has one product "Onivyde" recently approved on the market for a type of pancreatic cancer as well as in late stage trials for other indications. Onivyde also just got the "thumbs up" from The European Medicines Agency's Committee for Medicinal Products for Human Use {CHMP}. It will be marketed there by Shire (NASDAQ:SHPG) which is Merrimack's marketing and distribution partner outside the United States.
Another compound in Merrimack's pipeline (seribantumab) recently received Fast Track review for the treatment of patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer. Merrimack has a market capitalization of under $700 million, a stock price under $6.00 a share and has a median price target by the analysts that cover it of $12 according to Tipranks. For a more detailed analysis of why I like Merrimack, click here.
http://seekingalpha.com/article/3994487-small-biotech-moving-risk-curve?v=1470150549&commenter=1&comments=show
And his previous write up:
http://seekingalpha.com/article/3961298-biotech-forum-daily-digest-mercks-pyrrhic-victory-gilead-amgens-patent-win-spotlight
Recent MACK News
- Merrimack Receives $225 Million Milestone Payment from Ipsen • Business Wire • 03/27/2024 08:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/07/2024 09:42:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:39:03 PM
- Merrimack Reports Full Year 2023 Financial Results • Business Wire • 03/07/2024 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:15:29 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 03/07/2024 05:29:51 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/05/2024 09:44:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:20:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/13/2024 09:26:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:22:56 PM
- Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) • Business Wire • 02/13/2024 09:18:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/25/2024 09:05:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 09:05:12 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/13/2023 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/11/2023 09:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 11:59:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 10:09:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 08:30:25 PM
- Merrimack Reports Third Quarter 2023 Financial Results • Business Wire • 11/02/2023 08:30:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 08/14/2023 08:05:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2023 08:06:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 08:36:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/03/2023 08:31:02 PM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM